Eurofins Announces the Successful Closing of the Acquisition of a Controlling Stake in Emory Genetics Laboratory
01 September 2015 - 3:30PM
Business Wire
Regulatory News:
Eurofins (Paris:ERF):
Eurofins Scientific (EUFI.PA), the global leader in
bio-analytical testing, and one of the world leaders in genomic
services, announces the successful closing of the transaction to
acquire a 75% stake in Emory Genetics Laboratory (“EGL”) from Emory
University’s School of Medicine, as communicated on the 29th of
June, 2015.
EGL is renowned for testing rare genetic disorders, and leads
the industry in gene panels including cancer testing and exome
sequencing to aid diagnosis, prognosis, management and targeted
drug therapy (e.g., personalized medicine), in addition to expanded
carrier testing capabilities. The lab serves over 400 institutional
clients (hospitals and other commercial laboratories) across the
US, and expects to generate revenues in excess of US$ 15m for 2015.
Henceforth, the company will be known as EGL Genetic Diagnostics,
LLC, a joint venture company of Eurofins and Emory University.
For more information about Eurofins, please visit
www.eurofins.com
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific is the world leader in food, environment and
pharmaceutical products testing. It is also one of the global
market leaders in agroscience, genomics, discovery pharmacology and
central laboratory services. In addition, Eurofins is one of the
key emerging players in specialty clinical diagnostic testing in
Europe and the USA.
With 19,000 staff in around 200 laboratories across 38
countries, Eurofins offers a portfolio of over 130,000 reliable
analytical methods for evaluating the safety, identity,
composition, authenticity, origin and purity of biological
substances and products, as well as for innovative clinical
diagnostic. The Group provides its customers with high-quality
services, accurate results on time and expert advice by its highly
qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgement
of Eurofins Scientific’ management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150831006338/en/
Eurofins Scientific GroupInvestor RelationsPhone: +32 2 766
1620ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Sep 2024 to Oct 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Oct 2023 to Oct 2024